Effects of Ranitidine on pulmonary function tests of patients with chronic obstructive pulmonary disease

Basit Öğe Kaydı
dc.authoridÇakır, Münire/0000-0001-8650-3722;
dc.authorwosidÇakır, Münire/AAC-6583-2020
dc.authorwosidKoksal, Nurhan/AAA-3249-2022
dc.authorwosidKöksal, Nurhan/AAG-5849-2021
dc.contributor.authorHasanoglu, HC
dc.contributor.authorYidirim, Z
dc.contributor.authorHasanoglu, A
dc.contributor.authorOzcan, C
dc.contributor.authorGokirmak, M
dc.contributor.authorKoksal, N
dc.contributor.authorKalkan, S
dc.date.accessioned2024-08-04T20:13:18Z
dc.date.available2024-08-04T20:13:18Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractSince the incidence of peptic ulcer and gastroesophageal reflux (GER) is more common in patients with chronic obstructive pulmonary disease (COPD) than normal population, H-2 receptor blockers are given more extensively to COPD patients. This study evaluated the effects of Ranitidine on pulmonary function tests (PFT) of the patients having COPD and peptic ulcer or GER, and of healthy volunteers. Fifty milligrams of Ranitidine was given intravenously to 30 COPD patients and 25 healthy volunteers. PFT were done before and 15, 30, 60, 120 min after Ranitidine injection. Although mean forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and forced midexpiratory flow rate (FEF25-75%) Of COPD patients were found to be decreased 60 and 120 min after Ranitidine injection, the decrements were statistically insignificant. The decrements in PFT of healthy volunteers were also not statistically significant. H-2 receptor blockers can be used safely for treatment of gastrointestinal disorders in COPD patients who have mild or moderate obstruction. Minimal decreases in FEV1 and FVC due to treatment by H-2 receptor blockers may clinically worsen COPD patients who have severe obstruction. (C) 2003 Elsevier Science Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/S1043-6618(03)00012-4
dc.identifier.endpage539en_US
dc.identifier.issn1043-6618
dc.identifier.issue6en_US
dc.identifier.pmid12742008en_US
dc.identifier.scopus2-s2.0-0037624823en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage535en_US
dc.identifier.urihttps://doi.org/10.1016/S1043-6618(03)00012-4
dc.identifier.urihttps://hdl.handle.net/11616/93524
dc.identifier.volume47en_US
dc.identifier.wosWOS:000183218900012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Ltd- Elsevier Science Ltden_US
dc.relation.ispartofPharmacological Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOPDen_US
dc.subjectH-2 receptor blockersen_US
dc.subjectRanitidineen_US
dc.subjectpulmonary function testsen_US
dc.subjectgastroesophageal refluxen_US
dc.subjectpeptic ulceren_US
dc.titleEffects of Ranitidine on pulmonary function tests of patients with chronic obstructive pulmonary diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu